Delivery Order SPE2DB22D3009-SPE2DB25FBD37
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,727.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 12, 2025, with completion due by August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $24,225.78 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on June 25, 2025, with completion scheduled for June 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used for weight management, represents part of the pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,596.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 27, 2025, with completion expected by August 28, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $6,098.82 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on August 22, 2025, with completion scheduled for August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used for weight management, represents part of the pharmaceutical distributor's...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD37Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $9,307.19 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing indefinite delivery contract. The contract requires delivery by August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a branded GLP-1 receptor agonist medication used for weight management in eligible patients. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military healthcare systems, the Defense Health Agency, and other government healthcare entities worldwide. The company's contract portfolio with DLA demonstrates consistent capability to fulfill federal pharmaceutical procurement requirements across multiple therapeutic domains through competitive, firm fixed price mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 8/15/25 |